Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation

Non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), who had malignant disease. However, their use in cancer patients increases and real-life evidence for their effectiveness...

Full description

Saved in:
Bibliographic Details
Main Authors: Anetta Undas, Leszek Drabik
Format: Article
Language:English
Published: KARE Publishing 2019-12-01
Series:Anatolian Journal of Cardiology
Subjects:
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=anatoljcardiol&un=AJC-30766
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850239245489274880
author Anetta Undas
Leszek Drabik
author_facet Anetta Undas
Leszek Drabik
author_sort Anetta Undas
collection DOAJ
description Non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), who had malignant disease. However, their use in cancer patients increases and real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs in cancer patients with AF and the current expert opinions on this subject have been summarized in this review article.
format Article
id doaj-art-1e88a4b4c6924c5d924979d6ea3a9d8a
institution OA Journals
issn 2149-2263
language English
publishDate 2019-12-01
publisher KARE Publishing
record_format Article
series Anatolian Journal of Cardiology
spelling doaj-art-1e88a4b4c6924c5d924979d6ea3a9d8a2025-08-20T02:01:13ZengKARE PublishingAnatolian Journal of Cardiology2149-22632019-12-01231101810.14744/AnatolJCardiol.2019.30766AJC-30766Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillationAnetta Undas0Leszek Drabik1John Paul II Hospital, Krakow, PolandJohn Paul II Hospital, Krakow, PolandNon-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), who had malignant disease. However, their use in cancer patients increases and real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs in cancer patients with AF and the current expert opinions on this subject have been summarized in this review article.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=anatoljcardiol&un=AJC-30766anticoagulationatrial fibrillationbleedingcancerdirect oral anticoagulants
spellingShingle Anetta Undas
Leszek Drabik
Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
Anatolian Journal of Cardiology
anticoagulation
atrial fibrillation
bleeding
cancer
direct oral anticoagulants
title Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
title_full Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
title_fullStr Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
title_full_unstemmed Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
title_short Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation
title_sort non vitamin k antagonist oral anticoagulants noacs in cancer patients with atrial fibrillation
topic anticoagulation
atrial fibrillation
bleeding
cancer
direct oral anticoagulants
url https://jag.journalagent.com/z4/download_fulltext.asp?pdir=anatoljcardiol&un=AJC-30766
work_keys_str_mv AT anettaundas nonvitaminkantagonistoralanticoagulantsnoacsincancerpatientswithatrialfibrillation
AT leszekdrabik nonvitaminkantagonistoralanticoagulantsnoacsincancerpatientswithatrialfibrillation